Associate Director, Safety Scientist
Company: Kura Oncology
Location: Boston
Posted on: April 15, 2024
|
|
Job Description:
Are you ready to join a team committed to making a meaningful
impact on cancer treatment through the discovery and development of
precision medicines? At Kura Oncology, you have an opportunity to
be a part of something bigger, with a lasting impact that you can
be proud of.
At Kura Oncology, we are working to change the paradigm and improve
the science of cancer treatment. As an organization, we strive to
cultivate a diverse and talented professional culture driven to
develop precision medicine therapeutics.
As we continue to build a leading biotech organization with a
strong culture, a patient-focused mindset and a team focused on
relentless execution, we are looking for innovative, passionate
professionals to join us and make our vision a reality.
To succeed at Kura, you will need to have a demonstrated ability
for excellence in drug discovery and development and a roll-up your
sleeves attitude. The ideal candidate will possess a values-driven
work style where integrity and grit drive all behaviors, decisions,
and actions.
Essential Job Functions
Job Requirements
Kura's Values that are used for candidate selection and performance
assessments:
The Kura Package
Kura Oncology is a clinical-stage biopharmaceutical company
discovering and developing personalized therapeutics for the
treatment of solid tumors and blood cancers. The company's diverse
pipeline consists of small molecules that target cancer signaling
pathways where there is a strong scientific and clinical rationale
to improve outcomes by identifying those patients most likely to
benefit from treatment. Kura Oncology's approach to drug
development is focused on rapidly translating novel science into
life-saving medicines. Our goal is to help patients with cancer
lead better, longer lives. Kura Oncology has offices in San Diego,
California, and Boston, Massachusetts.
Kura's pipeline consists of three investigational drug candidates:
ziftomenib, tipifarnib and KO-2806. Ziftomenib is a once-daily,
oral drug candidate targeting the menin-KMT2A protein-protein
interaction for the treatment of genetically defined AML patients
with high unmet need. Ziftomenib is currently enrolling patients in
a Phase 2 registration-directed trial (KOMET-001) in NPM1-mutant
relapsed or refractory AML. Kura is preparing to initiate multiple
Phase 1 trials to evaluate ziftomenib in combination with current
standards of care in earlier lines of therapy and across multiple
patient populations, including NPM1-mutant and KMT2A-rearranged
AML. Tipifarnib, a potent and selective FTI, is currently in a
Phase 1/2 trial (KURRENT-HN) in combination with alpelisib for
patients with PIK3CA-dependent HNSCC. Kura intends to evaluate
KO-2806, a next-generation FTI, in a Phase 1 dose-escalation trial
(FIT-001) as a monotherapy and in combination with other targeted
therapies in adult patients with advanced solid tumors. For
additional information, please visit Kura's website at .
Kura Oncology is committed to creating a diverse environment and is
proud to be an equal opportunity employer. All qualified applicants
will receive consideration for employment without regard to race,
color, religion, gender, gender identity or expression, sexual
orientation, national origin, genetics, disability, age, or veteran
status.
Keywords: Kura Oncology, Newton , Associate Director, Safety Scientist, Executive , Boston, Massachusetts
Click
here to apply!
|